Upregulated FGFR1 expression is associated with the transition of hormone-naive to castrate-resistant prostate cancer

British Journal of Cancer

Volumn 105, Issue 9, 2011, Pages 1362-1369

  Armstrong, K ^a   Ahmad, I ^b,c   Kalna, G ^b   Tan, S S ^b,c   Edwards, J ^c   Robson, C N ^a   Leung, H Y ^a,b,c  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

fibroblast growth factor receptor 1; formalin fixed; gene expression analysis; hormone naive and castrate resistant prostate cancer; paraffin embedded samples; prostate cancer

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1;

ARTICLE; CANCER RELAPSE; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; IN VITRO STUDY; MALE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; CASTRATION; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PROSTATIC NEOPLASMS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTORS, ANDROGEN; RECURRENCE; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 80054997476     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.367     Document Type: Article

References (27)

1. Acevedo VD, Gangula RD, Freeman KW, Li R, Zhang Y, Wang F, Ayala GE, Peterson LE, Ittmann M, Spencer DM (2007) Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell 12(6): 559-571 (Pubitemid 350199071)
2. Aggarwal R, Ryan CJ (2011) Castration-resistant prostate cancer: targeted therapies and individualized treatment. Oncologist 16(3): 264-275
3. Berger W, Setinek U, Mohr T, Kindas-Mugge I, Vetterlein M, Dekan G, Eckersberger F, Caldas C, Micksche M (1999) Evidence for a role of FGF-2 and FGF receptors in the proliferation of non-small cell lung cancer cells. Int J Cancer 83(3): 415-423 (Pubitemid 29455767)
4. Bibikova M, Talantov D, Chudin E, Yeakley JM, Chen J, Doucet D, Wickham E, Atkins D, Barker D, Chee M, Wang Y, Fan JB (2004a) Quantitative gene expression profiling in formalin-fixed, paraffin-embedded tissues using universal bead arrays. Am J Pathol 165(5): 1799-1807 (Pubitemid 39435177)
5. Bibikova M, Yeakley JM, Chudin E, Chen J, Wickham E, Wang-Rodriguez J, Fan JB (2004b) Gene expression profiles in formalin-fixed, paraffin-embedded tissues obtained with a novel assay for microarray analysis. Clin Chem 50(12): 2384-2386 (Pubitemid 39552178)
6. Bibikova M, Yeakley JM, Wang-Rodriguez J, Fan JB (2008) Quantitative expression profiling of RNA from formalin-fixed, paraffin-embedded tissues using randomly assembled bead arrays. Methods Mol Biol (Clifton, NJ) 439: 159-177
7. Chudin E, Kruglyak S, Baker SC, Oeser S, Barker D, McDaniel TK (2006) A model of technical variation of microarray signals. J Comput Biol 13(4): 996-1003 (Pubitemid 43941647)
8. Cole C, Lau S, Backen A, Clamp A, Rushton G, Dive C, Hodgkinson C, McVey R, Kitchener H, Jayson GC (2010) Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer. Cancer Biol Ther 10(5): 495-504
9. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H (1994) Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54(20): 5474-5478
10. Devilard E, Bladou F, Ramuz O, Karsenty G, Dales JP, Gravis G, Nguyen C, Bertucci F, Xerri L, Birnbaum D (2006) FGFR1 and WT1 are markers of human prostate cancer progression. BMC Cancer 6: 272
11. Dunham-Ems SM, Lee YW, Stachowiak EK, Pudavar H, Claus P, Prasad PN, Stachowiak MK (2009) Fibroblast growth factor receptor-1 (FGFR1) nuclear dynamics reveal a novel mechanism in transcription control. Mol Biol Cell 20(9): 2401-2412
12. Dunham-Ems SM, Pudavar HE, Myers JM, Maher PA, Prasad PN, Stachowiak MK (2006) Factors controlling fibroblast growth factor receptor-1's cytoplasmic trafficking and its regulation as revealed by FRAP analysis. Mol Biol Cell 17(5): 2223-2235 (Pubitemid 44011738)
13. Edwards J, Krishna NS, Witton CJ, Bartlett JM (2003) Gene amplifications associated with the development of hormone-resistant prostate cancer. Clin Cancer Res 9(14): 5271-5281 (Pubitemid 37413579)
14. Fan JB, Yeakley JM, Bibikova M, Chudin E, Wickham E, Chen J, Doucet D, Rigault P, Zhang B, Shen R, McBride C, Li HR, Fu XD, Oliphant A, Barker DL, Chee MS (2004) A versatile assay for high-throughput gene expression profiling on universal array matrices. Genome Res 14(5): 878-885 (Pubitemid 38660505)
15. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18(3): 581-592 (Pubitemid 46359643)
16. Gatt ME, Zhao JJ, Ebert MS, Zhang Y, Chu Z, Mani M, Gazit R, Carrasco DE, Dutta-Simmons J, Adamia S, Minvielle S, Tai YT, Munshi NC, Avet-Loiseau H, Anderson KC, Carrasco DR (2010) MicroRNAs 15a/16-1 function as tumor suppressor genes in multiple myeloma. Blood 117(26): 7188
17. Halkidou K, Gnanapragasam VJ, Mehta PB, Logan IR, Brady ME, Cook S, Leung HY, Neal DE, Robson CN (2003) Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene 22(16): 2466-2477 (Pubitemid 36560730)
18. Mencia N, Selga E, Rico I, de Almagro MC, Villalobos X, Ramirez S, Adan J, Hernandez JL, Noe V, Ciudad CJ (2010) Overexpression of S100A4 in human cancer cell lines resistant to methotrexate. BMC Cancer 10: 250
19. Parra E, Ferreira J (2010) The effect of siRNA-Egr-1 and camptothecin on growth and chemosensitivity of breast cancer cell lines. Oncol Rep 23(4): 1159-1165
20. Reid AH, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC, Molife LR, Hunt J, Messiou C, Parker C, Dearnaley D, Swennenhuis JF, Terstappen LW, Lee G, Kheoh T, Molina A, Ryan CJ, Small E, Scher HI, de Bono JS (2010) Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 28(9): 1489-1495
21. Rigas AC, Robson CN, Curtin NJ (2007) Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer. Oncogene 26(55): 7611-7619 (Pubitemid 350224225)
22. Sahadevan K, Darby S, Leung HY, Mathers ME, Robson CN, Gnanapragasam VJ (2007) Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. J Pathol 213(1): 82-90 (Pubitemid 47354569)
23. Scher HI, Morris MJ, Kelly WK, Schwartz LH, Heller G (2005) Prostate cancer clinical trial end points: 'RECIST' ing a step backwards. Clin Cancer Res 11(14): 5223-5232 (Pubitemid 41003710)
24. Shen HC, Balk SP (2009) Development of androgen receptor antagonists with promising activity in castration-resistant prostate cancer. Cancer Cell 15(6): 461-463
25. Tan SS, Ahmad I, Bennett HL, Singh L, Nixon C, Seywright M, Barnetson RJ, Edwards J, Leung HY (2010) GRP78 up-regulation is associated with androgen receptor status, Hsp70-Hsp90 client proteins and castrate-resistant prostate cancer. J Pathol 223(1): 81-87
26. Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, Natrajan R, Marchio C, Iorns E, Mackay A, Gillett C, Grigoriadis A, Tutt A, Reis-Filho JS, Ashworth A (2010) FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 70(5): 2085-2094
27. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K, Sawyers CL (2010) Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci USA 107(39): 16759-16765